Phenotypes Associated with This Genotype

Genotype
MGI:3789333

• Allelic Composition: En1^{tm7(cre/ESR1)Alj}/En1⁺; En2^tm2Alj/En2^tm2Alj; Gt(ROSA)26Sor^tm1Sor/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129S1/Sv * 129S4/SvJaeSor * 129S6/SvEvTac * 129X1/SvJ * Swiss Webster

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

nervous system

decreased rhombomere 1 size ( J:134516 )

• when tamoxifen is administered at E10.5, rhombomere 1 (r1) is reduced in size in mutants at E12.5

• anterior r1 cells contribute to more lateral regions of vermis than normal

decreased midbrain size ( J:134516 )

• when tamoxifen is administered at E10.5, mesencephalon is reduced in size at E12.5 relative to normal

• marked cells in posterior mesencephalon do not expand normally

abnormal tectum morphology ( J:134516 )

• when tamoxifen is administered at E10.5, size of marked domain is smaller than wild-type at E16.5

• in adults, marked domain in tectum is greatly reduced compared to wild-type; marked domain is restricted to remaining region of inferior colliculus

abnormal cerebellum morphology ( J:134516 )

• when tamoxifen is administered at E10.5, size of marked cell population is wider in mutants than in controls at E16.5

• in adults, marked domain is broader than normal

abnormal cerebellum vermis morphology ( J:134516 )

• in adults, vermis is reduced in size

embryo

decreased rhombomere 1 size ( J:134516 )

• when tamoxifen is administered at E10.5, rhombomere 1 (r1) is reduced in size in mutants at E12.5

• anterior r1 cells contribute to more lateral regions of vermis than normal